NUROFEN PLUS

국가: 이스라엘

언어: 영어

출처: Ministry of Health

지금 구매하세요

환자 정보 전단 환자 정보 전단 (PIL)
17-08-2016
제품 특성 요약 제품 특성 요약 (SPC)
18-08-2016

유효 성분:

CODEINE AS HEMIHYDRATE; IBUPROFEN

제공처:

RECKITT BENCKISER (NEAR EAST) LTD

ATC 코드:

M01AE51

약제 형태:

TABLETS

구성:

IBUPROFEN 200 MG; CODEINE AS HEMIHYDRATE 10 MG

관리 경로:

PER OS

처방전 유형:

Not required

Manufactured by:

RECKITT BENCKISER HEALTHCARE INTERNATIONAL LTD, UK

치료 그룹:

IBUPROFEN, COMBINATIONS

치료 영역:

IBUPROFEN, COMBINATIONS

치료 징후:

For short term use for the relief of acute (short lasting) moderate pain, such as rheumatic pain (arthritis), muscular pain, backaches, neuralgia, migraine, headache, dental pain and menstrual pain.

승인 날짜:

2015-01-31

제품 특성 요약

                                NUROFEN PLUS Tab 25. 12. 2005, RH
"
ע עבקנ הז ןולע טמרופ
"
רשואו קדבנ ונכותו תואירבה דרשמ י
."
“This leaflet format has been determined by the Ministry of Health
and the content thereof has been
checked and approved.”
NUROFEN
® PLUS
TABLETS
COMPOSITION
Each tablet contains:
_Active Ingredient _
Ibuprofen
200
mg
Codeine phosphate hemihydrate 12.8 mg
(equivalent to codeine 10 mg)
_Other Ingredients _
Cellulose, microcrystalline, sodium starch glycollate (
_from potato starch_
), starch
pregelatinised (
_from maize, potato, or rice starch_
), hypromellose (hydroxypropylmethyl
cellulose), titanium dioxide (E 171), talc
PHARMACOLOGICAL PARTICULARS
_Pharmacodynamic Properties _
Ibuprofen is an analgesic which acts peripherally, inhibiting
prostaglandin synthesis
and the action of chemical mediators of pain. Codeine is a narcotic
analgesic acting
on central opiate receptors, although its pharmacological effects are
thought to be
due largely to its biotransformation to morphine.
The combination of a well tolerated peripheral analgesic with a
centrally acting
analgesic provides optimum pain relief with a lower potential for
producing side-
effects.
_Pharmacokinetic Properties _
The elimination half-life of both ibuprofen and codeine is
approximately three hours,
and both drugs are given three to fours times daily. The combination
of the two
drugs is therefore appropriate from a pharmacokinetic viewpoint; the
tablet exhibits
normal release characteristics for both active substances.
INDICATIONS
For the relief of pain in such conditions as: rheumatic and muscular
pain, backache,
neuralgia, migraine, headache, dental pain, dysmenorrhoea,
feverishness, symptoms
of colds and influenza.
CONTRAINDICATIONS
Known hypersensitivity to the drug or to any ingredient of the
preparation.
Patients with a history of, or existing peptic ulceration.
Patients with severe hepatic failure, severe renal failure, severe
heart failure.
Previous allergic reaction to any other pain reliever / fever re
                                
                                전체 문서 읽기
                                
                            

다른 언어로 된 문서

환자 정보 전단 환자 정보 전단 아랍어 04-08-2015
환자 정보 전단 환자 정보 전단 히브리어 17-08-2016

문서 기록보기